A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-Operatively.

Trial Profile

A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-Operatively.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Bortezomib (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2012 Planned End Date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 18 May 2011 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.
    • 18 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top